The final overall survival (OS) results of the FLAURA2 trial support osimertinib plus chemotherapy as the new first-line standard of care for EGFR-mutated non-small cell lung cancer (NSCLC), according ...
CHICAGO -- Incorporating the investigational, oral selective estrogen receptor degrader (SERD) camizestrant at the first sign of emerging ESR1 mutations extended the ...
Thin Blue Line Benefits Association, an insurance company targeting retired first responders, is accused of fraudulent practices in Ohio. The company allegedly collected premiums while failing to pay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback